All In Biotech

Drug Trial Radar · NCT05789745

A Study to Evaluate Plasma Gelsolin in Healthy Volunteers

Single-center, Randomized, Double-blind, Placebo-controlled, Ascending-Dose Study to Evaluate the Safety and Pharmacokinetics of Recombinant Human Plasma Gelsolin (Rhu-pGSN) After Intravenous Administration to Healthy Volunteers

Last checked: Nov 20, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

32

Actual

Start

Mar 14, 2023

Primary completion

May 24, 2023

Study completion May 24, 2023

Sponsor

Lead sponsor
BioAegis Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Mar 29, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Study BTI-101 is a Phase 1, randomized, double-blind, placebo-controlled, dose escalation, parallel design study to evaluate the safety, tolerability, and pharmacokinetics of IV rhu-pGSN or saline placebo administered as 5 doses each of 6, 12, 18, or 24 mg/kg of body weight. Each of 4 dosing cohorts will include 8 subjects randomized 3:1 rhu-pGSN:placebo (6 rhu-pGSN subjects:2 placebo subjects). Subjects will be healthy adult volunteers 18-55 years of age.

Conditions

  • Volunteers
  • Healthy

Interventions

  • Recombinant human plasma gelsolinDrug

    intravenous administration of either 6, 12, 18, or 24 mg/kg at time 0, 12, 36, 60 and 84 hours

  • placeboOther

    intravenous administration of saline control at time 0, 12, 36, 60 and 84 hours

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse EventsTime frame: 28 days
  2. Serious Adverse EventsTime frame: 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network

    Saint Paul, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.